Examples of drugs where the population of interest could be expanded to treat ccRCC include: Temsirolimus, which is undergoing ongoing trials as a treatment for FBXW7-positive solid tumours78,79, nilotinib for ABL1 mutations80, niraparib for BAP1 mutations81, Tazemetostat hydrobromide for SMARCA4 mutated cancers82,83, olaparib with pembrolizumab for ARID2-positive melanoma84, and alpelisib for PIK3CA in ER-positive metastatic breast cancer85,86. This evidence concerns the gene PIK3CA and nonpapillary renal cell carcinoma.